70.33
Corcept Therapeutics Inc stock is traded at $70.33, with a volume of 866.15K.
It is down -0.92% in the last 24 hours and up +1.81% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$70.98
Open:
$71.17
24h Volume:
866.15K
Relative Volume:
0.72
Market Cap:
$7.41B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
55.82
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-1.97%
1M Performance:
+1.81%
6M Performance:
+10.69%
1Y Performance:
+105.16%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CORT
Corcept Therapeutics Inc
|
70.33 | 7.56B | 628.56M | 141.82M | 142.60M | 1.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-06-23 | Upgrade | Truist | Hold → Buy |
Apr-11-23 | Initiated | SVB Securities | Market Perform |
Apr-04-23 | Initiated | Piper Sandler | Overweight |
Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
Aug-01-22 | Downgrade | Truist | Buy → Hold |
Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
Jun-27-22 | Resumed | Canaccord Genuity | Buy |
Feb-02-22 | Initiated | Canaccord Genuity | Buy |
Jan-28-22 | Initiated | Truist | Buy |
Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
Sep-24-19 | Initiated | Jefferies | Buy |
Sep-06-19 | Initiated | H.C. Wainwright | Buy |
Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
Aug-10-18 | Reiterated | Stifel | Hold |
May-31-18 | Downgrade | Stifel | Buy → Hold |
Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
Aug-31-17 | Initiated | Stifel | Buy |
Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
Apr-21-15 | Initiated | FBR Capital | Outperform |
Jan-13-14 | Downgrade | Stifel | Buy → Hold |
Aug-09-13 | Downgrade | Janney | Buy → Neutral |
Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Intraday Action & High Return Trade Guides - classian.co.kr
With 70% Institutional Ownership, Corcept Therapeutics Incorporated (NASDAQ:CORT) Is a Favorite Amongst the Big Guns - 富途牛牛
What Technical Tools Say About Corcept Therapeutics Incorporated Recovery2025 Trading Volume Trends & Safe Capital Growth Stock Tips - metal.it
Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant - MSN
Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion - TipRanks
Watch for Bullish Crossover in Corcept Therapeutics IncorporatedJuly 2025 Closing Moves & Consistent Profit Focused Trading Strategies - beatles.ru
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook - Yahoo Finance
5 Must-Read Analyst Questions From Corcept’s Q2 Earnings Call - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,512,452, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics director Swisher sells $159k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics officer sells $2.5M in shares By Investing.com - Investing.com Australia
Corcept therapeutics director Swisher sells $159k in shares - Investing.com
Corcept therapeutics officer sells $2.5M in shares - Investing.com
Corcept Therapeutics Announces CDO William Guyer's Share Buy and Sell Transactions - AInvest
Corcept Therapeutics: Pioneering a $2.8B Market in Type 2 Diabetes via Hypercortisolism Treatment - AInvest
Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT) - Seeking Alpha
Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension - TipRanks
Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study - TipRanks
Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem - Yahoo Finance
Assessing the Impact of Pre-Scheduled Insider Sales at Corcept Therapeutics on Investor Confidence and Market Dynamics - AInvest
Corcept Therapeutics Insider Sold Shares Worth $2,373,237, According to a Recent SEC Filing - MarketScreener
Corcept Therapeutics Insider Sold Shares Worth $393,128, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics officer Lyon sells $393k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock By Investing.com - Investing.com India
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock - Investing.com
Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com
How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News
How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News
How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News
Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest
What catalysts could drive Corcept Therapeutics Incorporated stock higher in 2025Dynamic profit opportunities - Jammu Links News
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFastest return on investment - Jammu Links News
What are the latest earnings results for Corcept Therapeutics IncorporatedInvest smarter with daily stock recommendations - Jammu Links News
What analysts say about Corcept Therapeutics Incorporated stockRealize exceptional returns through smart trading - Jammu Links News
CORT's Q2 Earnings Beat and Pipeline Momentum: A Case for Revisiting the Downside as a Buy Opportunity - AInvest
When is Corcept Therapeutics Incorporated stock expected to show significant growthTremendous financial leverage - Jammu Links News
Corcept Therapeutics (CORT): A High-Conviction Buy Amidst Breakthroughs in Cortisol-Modulating Therapies - AInvest
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Published on: 2025-08-02 05:25:16 - metal.it
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - MSN
Corcept Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Corcept Therapeutics Incorporated Recovery Hinges on Volume BreakoutNews Based Entry Opportunity Alerts Detected - metal.it
Corcept Faces Growing Pains As Earnings Miss The Mark - Finimize
Corcept Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $121 to $145 - 富途牛牛
Corcept Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Declines 1% - AInvest
Corcept Therapeutics Q2 CY2025: Revenue Misses, Earnings BeatNews and Statistics - IndexBox
Corcept Therapeutics shares fall 3.38% premarket after Q2 revenue misses estimates. - AInvest
Corcept: Q2 Earnings Snapshot - Connecticut Post
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Swisher Daniel N JR | Director |
Aug 11 '25 |
Sale |
72.30 |
2,200 |
159,060 |
0 |
Guyer William | Chief Development Officer |
Aug 08 '25 |
Option Exercise |
21.65 |
35,007 |
757,902 |
40,494 |
Guyer William | Chief Development Officer |
Aug 08 '25 |
Sale |
71.77 |
35,007 |
2,512,452 |
5,487 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):